Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena hopes lower concentration of obesity drug in human brain will reassure FDA

This article was originally published in Scrip

Executive Summary

Arena Pharmaceuticals and commercial partner Eisai Co said that a small nine-patient trial in obese volunteers of the experimental obesity drug lorcaserin (Lorqess) shows that the drug appears to concentrate less in the brains of humans than it does in rats. The partners hope that the finding may ease concerns of the US FDA that there is human relevance of the observation of lorcaserin-emergent brain astrocytoma in male rats.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel